$PACB

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

PacBio designs, develops, and manufactures sequencing solutions for scientists and clinical researchers at academic and government research institutions, laboratories, genome centers, hospitals, research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. Its HiFi long-read sequencing technology supports research in human genomics, plant and animal sciences, infectious disease and microbiology, oncology, and other applications. PacBio sells sequencing instruments, including its Revio, Vega, and Sequel systems, along with SMRT Cells, reagents, application-specific workflows, and sequencing services. Customers also buy consumables such as reagent kits and targeted sequencing products. PacBio markets through a global sales force and distribution partners. Its products are labeled and sold for research use only. The company is headquartered in Menlo Park, California, where it also operates a key manufacturing and service facility.

AlphAI earnings readQ3 FY2026 · NOV 4PacBio Announces Third Quarter 2026 Financial ResultsVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $PACB in the last 7 days.

No SEC Form 4 filings for $PACB in the last 30 days.

See all $PACB insider activity →
High

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB): Entry into a Material Definitive Agreement

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. On November 10, 2026, Pacific Biosciences of California, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Allen & Company LLC (“Allen”) to sell shares of the Company’s common stock, par value $

PACB sentiment & insider activity

Recent PACB coverage spans financial news, earnings and corporate actions.

What's driving PACB

AlphAI scores every news story that mentions PACB with an AI model for sentiment and relevance, and aggregates insider trades from PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PACB

Score
$PACBHighOffering· $100M · proposed

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB): Entry into a Material Definitive Agreement

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. On November 10, 2026, Pacific Biosciences of California, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Allen & Company LLC (“Allen”) to sell shares of the Company’s common stock, par value $

What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call

Pacific Biosciences (PACB) reported Q3 earnings, with Revio consumables pull-through at $204,000 per system. Instrument revenue rose to $13.2M, with 15 Revio and 35 Vega systems sold. Clinical business grew over 20% YoY, now exceeding 20% of total business. Non-GAAP net loss narrowed to $32.8M, with cash at $199.4M. The company maintained its 2026 outlook and expects cash flow breakeven in 2028.

$PACBMedEarnings

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB): PacBio Announces Third Quarter 2026 Financial Results

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PacBio Announces Third Quarter 2026 Financial Results MENLO PARK, Calif., November 4, 2026 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026. Recent Business Highlights • Delivered total revenue of $40

PacBio and Verily Health form genomic data collaboration

PacBio (PACB) and Verily Health have formed a multi-year collaboration to integrate PacBio's HiFi sequencing with Verily's data and AI platform. The partnership aims to combine long-read genomic data with clinical data for biomedical discovery and AI model training. Verily Pre Workbench will connect PacBio sequencing workflows for researchers. The companies plan to expand the integration across research organizations and biopharma.

Related tickers